yeah, but the previous Monday-Friday swing was from $89+ to like $127. can't really call bull/bear markets by a few days' action.
actually, i'm bitching because management lost me money, not because I did. and you're too old to use LOL.
...MYL is king. What a disaster this company is. A hostile takeover is their best strategy for building shareholder equity? Hi, what abut the 45% premium TEVA would have paid for the company months ago? Remember that?
Let's say you spend $80 a month for cable and decide you don't want to anymore. You're going to pick up Hulu for $10/month. You're still $70/month better off. So why not spend $9 on Netflix? And how about subscribing to some other service for $10/month. Now you're in for $29 instead of $80, which means you're winning. Any cord-cutting plan that people concoct is going to include Netflix. It just is. So the fuller the offerings are from other companies, the more this encourages cord-cutting and helps Netflix.
i haven't read a single thing about a takeover rumor beyond this stupid message board.
it's up today! but i hate to say it: it's probably a blip on a further downward slope. i sold yesterday morning at $295, and somehow the realities of ICPT seem a little clearer now that I'm out.
the thinking yesterday was that 2H of 2019 would be the earliest approval period. it's hard to believe that with GILD's resources they couldn't catch up to that timeline, since they're in PII with their NASH drug right now.
read the reports. they expect the drug to hit the market, if approved, 2H19 or 2020. it's a 72-week study, which brings just that phase to 2017's doorstep. you're dreaming, thinking this rolls out next year.
I think this would actually be pretty smart, although GILD did just buy, Phenex, a small player in the NASH space. The only thing buying ICPT would do is jump them from PII to PIII in the clinicals, right?
I'm long but am actually a little concerned myself about a late 2019 or even 2020 launch. that's a long time to wait for the candy everybody wants.